Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
AURO LAB. ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AURO LAB. Mar-23 |
ADCOCK INGRAM Jun-14 |
AURO LAB./ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 116 | 325 | - | |
Low | Rs | 53 | 234 | - | |
Sales per share (Unadj.) | Rs | 84.9 | 96.6 | - | |
Earnings per share (Unadj.) | Rs | 3.9 | -24.3 | - | |
Cash flow per share (Unadj.) | Rs | 5.6 | -20.2 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 54.9 | 75.8 | - | |
Shares outstanding (eoy) | m | 6.23 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.0 | 2.9 | 34.3% | |
Avg P/E ratio | x | 21.5 | -11.5 | -187.2% | |
P/CF ratio (eoy) | x | 14.9 | -13.9 | -107.7% | |
Price / Book Value ratio | x | 1.5 | 3.7 | 41.6% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 525 | 47,183 | 1.1% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 38 | 2,961 | 1.3% | |
Avg. sales/employee | Rs Th | 0 | 3,798.6 | - | |
Avg. wages/employee | Rs Th | 0 | 689.8 | - | |
Avg. net profit/employee | Rs Th | 0 | -957.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 529 | 16,307 | 3.2% | |
Other income | Rs m | 9 | 114 | 8.2% | |
Total revenues | Rs m | 538 | 16,421 | 3.3% | |
Gross profit | Rs m | 44 | -2,826 | -1.6% | |
Depreciation | Rs m | 11 | 704 | 1.5% | |
Interest | Rs m | 8 | 442 | 1.8% | |
Profit before tax | Rs m | 34 | -3,857 | -0.9% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 10 | 241 | 4.2% | |
Profit after tax | Rs m | 24 | -4,109 | -0.6% | |
Gross profit margin | % | 8.3 | -17.3 | -47.9% | |
Effective tax rate | % | 29.1 | -6.2 | -466.1% | |
Net profit margin | % | 4.6 | -25.2 | -18.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 354 | 11,944 | 3.0% | |
Current liabilities | Rs m | 181 | 6,720 | 2.7% | |
Net working cap to sales | % | 32.6 | 32.0 | 101.8% | |
Current ratio | x | 2.0 | 1.8 | 109.8% | |
Inventory Days | Days | 2 | 111 | 2.1% | |
Debtors Days | Days | 85,599 | 124 | 69,065.2% | |
Net fixed assets | Rs m | 206 | 6,962 | 3.0% | |
Share capital | Rs m | 62 | 76 | 82.3% | |
Net worth | Rs m | 342 | 12,799 | 2.7% | |
Long term debt | Rs m | 20 | 4,498 | 0.4% | |
Total assets | Rs m | 560 | 24,179 | 2.3% | |
Interest coverage | x | 5.2 | -7.7 | -67.7% | |
Debt to equity ratio | x | 0.1 | 0.4 | 16.7% | |
Sales to assets ratio | x | 0.9 | 0.7 | 140.1% | |
Return on assets | % | 5.8 | -15.2 | -38.3% | |
Return on equity | % | 7.1 | -32.1 | -22.2% | |
Return on capital | % | 11.8 | -19.8 | -59.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 33 | 1,392 | 2.4% | |
From Investments | Rs m | -51 | -427 | 11.9% | |
From Financial Activity | Rs m | -82 | 4,082 | -2.0% | |
Net Cashflow | Rs m | -100 | 5,047 | -2.0% |
Compare AURO LAB. With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare AURO LAB. With: SEQUENT SCIENTIFIC SHARON BIO-MEDICINE NATURAL CAPS SUN PHARMA DR. DATSONS LABS
After opening the day on positive note, Indian share markets reversed the trend as the session progressed and ended lower.